In Light of the LANDI-SEP Trial: New Evidence or Double Jeopardy?

Priyankar K Datta; Prachee Sathe; Anirban Bhattacharjee; Riddhi Kundu

doi:10.5005/jp-journals-10071-24881

SEARCH WITHIN CONTENT

Online First

In Light of the LANDI-SEP Trial: New Evidence or Double Jeopardy?

Priyankar K Datta, Prachee Sathe, Anirban Bhattacharjee, Riddhi Kundu

Keywords : Beta blockers, Heart rate, Septic shock

Citation Information : Datta PK, Sathe P, Bhattacharjee A, Kundu R. In Light of the LANDI-SEP Trial: New Evidence or Double Jeopardy?. Indian J Crit Care Med 2025; 29 (1):84-85.

DOI: 10.5005/jp-journals-10071-24881

License: CC BY-NC 4.0

Published Online: 30-12-2024

ARTICLE
REFERENCES

Abstract

PDF Share

Bhattacharjee A, Sathe P, Datta PK, Kundu R, Roy A, Baronia T. The clinical utility of targeted heart rate control in septic shock: A Systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Indian J Crit Care Med 2024;28(12):1170–1179. DOI: 10.5005/jp-journals-10071-24849.
Gudivada KK. Targeted heart rate control in sepsis: A promising path or a double-edged sword? J Crit Care Med 2024;28(12):1093–1095. DOI: 10.5005/jp-journals-10071-24868.
Rehberg S, Frank S, Černý V, Cihlář R, Borgstedt R, Biancofiore G, et al. Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med 2024;50(10):1622–1634. DOI: 10.1007/s00134-024-07587-1.

PDF Share